Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

ASH 2021: updates in FLT3 mutated AML

FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.

In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.

Date: 11th February 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter